Based on basic psychometric tests, the Norwegian version of the EPIC-26 showed acceptable reliability and validity for assessment of adverse effects after treatment of non-metastatic prostate cancer.
No takes yet. Share an insight, caveat, or question.
Fosså et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: